http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 20 Aug 2026 18:19:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MACROGENICS+INC+++++++++++For%3A+Aug+19++Filed+by%3A+Peters+Jeffrey+Stuart/26957375.html si-local-file:///var/storage/secattach/20260820/26957375.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MACROGENICS+INC+++++++++++For%3A+Aug+19++Filed+by%3A+Peters+Jeffrey+Stuart/26957375.html Thu, 20 Aug 2026 18:19:00 -0400 MGNX O.00725647 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MACROGENICS+INC+++++++++++For%3A+Aug+19++Filed+by%3A+Peters+Jeffrey+Stuart/26957375.html si-local-file:///var/storage/secattach/20260820/26957375.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MACROGENICS+INC+++++++++++For%3A+Aug+19++Filed+by%3A+Peters+Jeffrey+Stuart/26957375.html Thu, 20 Aug 2026 18:19:00 -0400 MGNX O.00725647 http://www.streetinsider.com/SEC+Filings/Form++144++++++++MACROGENICS+INC++++++++++++++++++++++++Filed+by%3A+Peters+Jeffrey+Stuart/26951172.html si-local-file:///var/storage/secattach/20260819/26951172.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++MACROGENICS+INC++++++++++++++++++++++++Filed+by%3A+Peters+Jeffrey+Stuart/26951172.html Wed, 19 Aug 2026 17:20:00 -0400 MGNX O.00725647 http://www.streetinsider.com/SEC+Filings/Form++144++++++++MACROGENICS+INC++++++++++++++++++++++++Filed+by%3A+Peters+Jeffrey+Stuart/26951172.html si-local-file:///var/storage/secattach/20260819/26951172.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++MACROGENICS+INC++++++++++++++++++++++++Filed+by%3A+Peters+Jeffrey+Stuart/26951172.html Wed, 19 Aug 2026 17:20:00 -0400 MGNX O.00725647 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MACROGENICS+INC+++++++++++For%3A+Aug+17++Filed+by%3A+Bonvini+Ezio/26944545.html si-local-file:///var/storage/secattach/20260818/26944545.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MACROGENICS+INC+++++++++++For%3A+Aug+17++Filed+by%3A+Bonvini+Ezio/26944545.html Tue, 18 Aug 2026 16:19:00 -0400 MGNX O.00725647 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MACROGENICS+INC+++++++++++For%3A+Aug+17++Filed+by%3A+Bonvini+Ezio/26944545.html si-local-file:///var/storage/secattach/20260818/26944545.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MACROGENICS+INC+++++++++++For%3A+Aug+17++Filed+by%3A+Bonvini+Ezio/26944545.html Tue, 18 Aug 2026 16:19:00 -0400 MGNX O.00725647 http://www.streetinsider.com/SEC+Filings/Form++144++++++++MACROGENICS+INC++++++++++++++++++++++++Filed+by%3A+SIEGEL+JAY+PHILIP/26939048.html si-local-file:///var/storage/secattach/20260817/26939048.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++MACROGENICS+INC++++++++++++++++++++++++Filed+by%3A+SIEGEL+JAY+PHILIP/26939048.html Mon, 17 Aug 2026 17:37:00 -0400 MGNX O.00725647 http://www.streetinsider.com/SEC+Filings/Form++144++++++++MACROGENICS+INC++++++++++++++++++++++++Filed+by%3A+SIEGEL+JAY+PHILIP/26939048.html si-local-file:///var/storage/secattach/20260817/26939048.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++MACROGENICS+INC++++++++++++++++++++++++Filed+by%3A+SIEGEL+JAY+PHILIP/26939048.html Mon, 17 Aug 2026 17:37:00 -0400 MGNX O.00725647 http://www.streetinsider.com/Analyst+PT+Change/MacroGenics+%28MGNX%29+PT+Raised+to+%2411+at+B.Riley/26935803.html B.Riley analyst Mayank Mamtani raised the price target on MacroGenics (NASDAQ: MGNX) to $11.00 (from $9.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/MacroGenics+%28MGNX%29+PT+Raised+to+%2411+at+B.Riley/26935803.html Mon, 17 Aug 2026 09:09:40 -0400 MGNX http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++MACROGENICS+INC+++++++++++For%3A+Jun+30/26931178.html si-local-file:///var/storage/secattach/20260814/26931178.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++MACROGENICS+INC+++++++++++For%3A+Jun+30/26931178.html Fri, 14 Aug 2026 16:27:00 -0400 MGNX O.00725647 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++MACROGENICS+INC+++++++++++For%3A+Jun+30/26931178.html si-local-file:///var/storage/secattach/20260814/26931178.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++MACROGENICS+INC+++++++++++For%3A+Jun+30/26931178.html Fri, 14 Aug 2026 16:27:00 -0400 MGNX O.00725647 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++MACROGENICS+INC++++++++++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26926344.html si-local-file:///var/storage/secattach/20260814/26926344.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++MACROGENICS+INC++++++++++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26926344.html Fri, 14 Aug 2026 10:22:00 -0400 MGNX O.00725647 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++MACROGENICS+INC++++++++++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26926344.html si-local-file:///var/storage/secattach/20260814/26926344.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++MACROGENICS+INC++++++++++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26926344.html Fri, 14 Aug 2026 10:22:00 -0400 MGNX O.00725647 http://www.streetinsider.com/Earnings/Macrogenics+%28MGNX%29+Misses+Q2+EPS+by+102c/26921636.html <p>Macrogenics (NASDAQ: MGNX) reported Q2 EPS of ($1.10), $1.02 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $32.83 million versus the consensus estimate of $59.14 million.</p><p>For earnings history and earnings-related data on Macrogenics (MGNX) <a href="http://www.streetinsider.com/ec_earnings.php?q=MGNX">click here</a>.</p> http://www.streetinsider.com/Earnings/Macrogenics+%28MGNX%29+Misses+Q2+EPS+by+102c/26921636.html Thu, 13 Aug 2026 16:23:55 -0400 MGNX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MACROGENICS+INC+++++++++++For%3A+Aug+13/26920998.html si-local-file:///var/storage/secattach/20260813/26920998.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MACROGENICS+INC+++++++++++For%3A+Aug+13/26920998.html Thu, 13 Aug 2026 16:09:00 -0400 MGNX O.00725647 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MACROGENICS+INC+++++++++++For%3A+Aug+13/26920998.html si-local-file:///var/storage/secattach/20260813/26920998.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MACROGENICS+INC+++++++++++For%3A+Aug+13/26920998.html Thu, 13 Aug 2026 16:09:00 -0400 MGNX O.00725647 http://www.streetinsider.com/Press+Releases/MacroGenics+Reports+Second+Quarter+2026+Financial+Results%2C+Streamlined+Operating+Model+and+Strengthened+Financial+Position/26920776.html <ul type="disc"><li style="margin-bottom:6pt; text-align:left;"><em>Announced sale of manufacturing operations (July 2026) for $122.5 million and transition to fully outsourced model with leaner, approximately 140-person workforce focused on novel therapeutics pipeline</em></li><li style="margin-bottom:6pt; text-align:left;"><em>Data presentations at ESMO planned for MGC026 (B7-H3 ADC) and lorigerlimab (PD-1 × CTLA-4)</em></li><li style="margin-bottom:6pt; text-align:left;"><em>MGC028 (ADAM9 ADC) dose escalation study ongoing; disclosure of preliminary clinical results planned for late 2026</em></li><li style="margin-bottom:6pt; text-align:left;"><em>MGC030 IND application submission cleared ahead of schedule, with first patient expected to be dosed in third quarter</em></li><li style="margin-bottom:6pt; text-align:left;"><em>Pro forma cash, cash equivalents and marketable securities of $327 million; cash runway guidance through 2028</em><br/><br/></li></ul> <p align="left">ROCKVILLE, http://www.streetinsider.com/Press+Releases/MacroGenics+Reports+Second+Quarter+2026+Financial+Results%2C+Streamlined+Operating+Model+and+Strengthened+Financial+Position/26920776.html Thu, 13 Aug 2026 16:05:00 -0400 A.06822034 A.50200911 MGNX O.00725647 O.06886563 O.20026344 http://www.streetinsider.com/Press+Releases/MacroGenics+Reports+Second+Quarter+2026+Financial+Results%2C+Streamlined+Operating+Model+and+Strengthened+Financial+Position/26920776.html <ul type="disc"><li style="margin-bottom:6pt; text-align:left;"><em>Announced sale of manufacturing operations (July 2026) for $122.5 million and transition to fully outsourced model with leaner, approximately 140-person workforce focused on novel therapeutics pipeline</em></li><li style="margin-bottom:6pt; text-align:left;"><em>Data presentations at ESMO planned for MGC026 (B7-H3 ADC) and lorigerlimab (PD-1 × CTLA-4)</em></li><li style="margin-bottom:6pt; text-align:left;"><em>MGC028 (ADAM9 ADC) dose escalation study ongoing; disclosure of preliminary clinical results planned for late 2026</em></li><li style="margin-bottom:6pt; text-align:left;"><em>MGC030 IND application submission cleared ahead of schedule, with first patient expected to be dosed in third quarter</em></li><li style="margin-bottom:6pt; text-align:left;"><em>Pro forma cash, cash equivalents and marketable securities of $327 million; cash runway guidance through 2028</em><br/><br/></li></ul> <p align="left">ROCKVILLE, http://www.streetinsider.com/Press+Releases/MacroGenics+Reports+Second+Quarter+2026+Financial+Results%2C+Streamlined+Operating+Model+and+Strengthened+Financial+Position/26920776.html Thu, 13 Aug 2026 16:05:00 -0400 A.06822034 A.50200911 MGNX O.00725647 O.06886563 O.20026344 http://www.streetinsider.com/Press+Releases/MacroGenics+Reports+Second+Quarter+2026+Financial+Results%2C+Streamlined+Operating+Model+and+Strengthened+Financial+Position/26920776.html <ul type="disc"><li style="margin-bottom:6pt; text-align:left;"><em>Announced sale of manufacturing operations (July 2026) for $122.5 million and transition to fully outsourced model with leaner, approximately 140-person workforce focused on novel therapeutics pipeline</em></li><li style="margin-bottom:6pt; text-align:left;"><em>Data presentations at ESMO planned for MGC026 (B7-H3 ADC) and lorigerlimab (PD-1 × CTLA-4)</em></li><li style="margin-bottom:6pt; text-align:left;"><em>MGC028 (ADAM9 ADC) dose escalation study ongoing; disclosure of preliminary clinical results planned for late 2026</em></li><li style="margin-bottom:6pt; text-align:left;"><em>MGC030 IND application submission cleared ahead of schedule, with first patient expected to be dosed in third quarter</em></li><li style="margin-bottom:6pt; text-align:left;"><em>Pro forma cash, cash equivalents and marketable securities of $327 million; cash runway guidance through 2028</em><br/><br/></li></ul> <p align="left">ROCKVILLE, http://www.streetinsider.com/Press+Releases/MacroGenics+Reports+Second+Quarter+2026+Financial+Results%2C+Streamlined+Operating+Model+and+Strengthened+Financial+Position/26920776.html Thu, 13 Aug 2026 16:05:00 -0400 A.06822034 A.50200911 MGNX O.00725647 O.06886563 O.20026344 http://www.streetinsider.com/Press+Releases/MacroGenics+Reports+Second+Quarter+2026+Financial+Results%2C+Streamlined+Operating+Model+and+Strengthened+Financial+Position/26920776.html <ul type="disc"><li style="margin-bottom:6pt; text-align:left;"><em>Announced sale of manufacturing operations (July 2026) for $122.5 million and transition to fully outsourced model with leaner, approximately 140-person workforce focused on novel therapeutics pipeline</em></li><li style="margin-bottom:6pt; text-align:left;"><em>Data presentations at ESMO planned for MGC026 (B7-H3 ADC) and lorigerlimab (PD-1 × CTLA-4)</em></li><li style="margin-bottom:6pt; text-align:left;"><em>MGC028 (ADAM9 ADC) dose escalation study ongoing; disclosure of preliminary clinical results planned for late 2026</em></li><li style="margin-bottom:6pt; text-align:left;"><em>MGC030 IND application submission cleared ahead of schedule, with first patient expected to be dosed in third quarter</em></li><li style="margin-bottom:6pt; text-align:left;"><em>Pro forma cash, cash equivalents and marketable securities of $327 million; cash runway guidance through 2028</em><br/><br/></li></ul> <p align="left">ROCKVILLE, http://www.streetinsider.com/Press+Releases/MacroGenics+Reports+Second+Quarter+2026+Financial+Results%2C+Streamlined+Operating+Model+and+Strengthened+Financial+Position/26920776.html Thu, 13 Aug 2026 16:05:00 -0400 A.06822034 A.50200911 MGNX O.00725647 O.06886563 O.20026344 http://www.streetinsider.com/Press+Releases/MacroGenics+Reports+Second+Quarter+2026+Financial+Results%2C+Streamlined+Operating+Model+and+Strengthened+Financial+Position/26920776.html <ul type="disc"><li style="margin-bottom:6pt; text-align:left;"><em>Announced sale of manufacturing operations (July 2026) for $122.5 million and transition to fully outsourced model with leaner, approximately 140-person workforce focused on novel therapeutics pipeline</em></li><li style="margin-bottom:6pt; text-align:left;"><em>Data presentations at ESMO planned for MGC026 (B7-H3 ADC) and lorigerlimab (PD-1 × CTLA-4)</em></li><li style="margin-bottom:6pt; text-align:left;"><em>MGC028 (ADAM9 ADC) dose escalation study ongoing; disclosure of preliminary clinical results planned for late 2026</em></li><li style="margin-bottom:6pt; text-align:left;"><em>MGC030 IND application submission cleared ahead of schedule, with first patient expected to be dosed in third quarter</em></li><li style="margin-bottom:6pt; text-align:left;"><em>Pro forma cash, cash equivalents and marketable securities of $327 million; cash runway guidance through 2028</em><br/><br/></li></ul> <p align="left">ROCKVILLE, http://www.streetinsider.com/Press+Releases/MacroGenics+Reports+Second+Quarter+2026+Financial+Results%2C+Streamlined+Operating+Model+and+Strengthened+Financial+Position/26920776.html Thu, 13 Aug 2026 16:05:00 -0400 A.06822034 A.50200911 MGNX O.00725647 O.06886563 O.20026344 http://www.streetinsider.com/Press+Releases/MacroGenics+Reports+Second+Quarter+2026+Financial+Results%2C+Streamlined+Operating+Model+and+Strengthened+Financial+Position/26920776.html <ul type="disc"><li style="margin-bottom:6pt; text-align:left;"><em>Announced sale of manufacturing operations (July 2026) for $122.5 million and transition to fully outsourced model with leaner, approximately 140-person workforce focused on novel therapeutics pipeline</em></li><li style="margin-bottom:6pt; text-align:left;"><em>Data presentations at ESMO planned for MGC026 (B7-H3 ADC) and lorigerlimab (PD-1 × CTLA-4)</em></li><li style="margin-bottom:6pt; text-align:left;"><em>MGC028 (ADAM9 ADC) dose escalation study ongoing; disclosure of preliminary clinical results planned for late 2026</em></li><li style="margin-bottom:6pt; text-align:left;"><em>MGC030 IND application submission cleared ahead of schedule, with first patient expected to be dosed in third quarter</em></li><li style="margin-bottom:6pt; text-align:left;"><em>Pro forma cash, cash equivalents and marketable securities of $327 million; cash runway guidance through 2028</em><br/><br/></li></ul> <p align="left">ROCKVILLE, http://www.streetinsider.com/Press+Releases/MacroGenics+Reports+Second+Quarter+2026+Financial+Results%2C+Streamlined+Operating+Model+and+Strengthened+Financial+Position/26920776.html Thu, 13 Aug 2026 16:05:00 -0400 A.06822034 A.50200911 MGNX O.00725647 O.06886563 O.20026344 http://www.streetinsider.com/Globe+Newswire/MacroGenics+Reports+Second+Quarter+2026+Financial+Results%2C+Streamlined+Operating+Model+and+Strengthened+Financial+Position/26920776.html <ul type="disc"><li style="margin-bottom:6pt; text-align:left;"><em>Announced sale of manufacturing operations (July 2026) for $122.5 million and transition to fully outsourced model with leaner, approximately 140-person workforce focused on novel therapeutics pipeline</em></li><li style="margin-bottom:6pt; text-align:left;"><em>Data presentations at ESMO planned for MGC026 (B7-H3 ADC) and lorigerlimab (PD-1 × CTLA-4)</em></li><li style="margin-bottom:6pt; text-align:left;"><em>MGC028 (ADAM9 ADC) dose escalation study ongoing; disclosure of preliminary clinical results planned for late 2026</em></li><li style="margin-bottom:6pt; text-align:left;"><em>MGC030 IND application submission cleared ahead of schedule, with first patient expected to be dosed in third quarter</em></li><li style="margin-bottom:6pt; text-align:left;"><em>Pro forma cash, cash equivalents and marketable securities of $327 million; cash runway guidance through 2028</em><br/><br/></li></ul> <p align="left">ROCKVILLE, http://www.streetinsider.com/Globe+Newswire/MacroGenics+Reports+Second+Quarter+2026+Financial+Results%2C+Streamlined+Operating+Model+and+Strengthened+Financial+Position/26920776.html Thu, 13 Aug 2026 16:05:00 -0400 A.06822034 A.50200911 MGNX O.00725647 O.06886563 O.20026344 http://www.streetinsider.com/Globe+Newswire/MacroGenics+Reports+Second+Quarter+2026+Financial+Results%2C+Streamlined+Operating+Model+and+Strengthened+Financial+Position/26920776.html <ul type="disc"><li style="margin-bottom:6pt; text-align:left;"><em>Announced sale of manufacturing operations (July 2026) for $122.5 million and transition to fully outsourced model with leaner, approximately 140-person workforce focused on novel therapeutics pipeline</em></li><li style="margin-bottom:6pt; text-align:left;"><em>Data presentations at ESMO planned for MGC026 (B7-H3 ADC) and lorigerlimab (PD-1 × CTLA-4)</em></li><li style="margin-bottom:6pt; text-align:left;"><em>MGC028 (ADAM9 ADC) dose escalation study ongoing; disclosure of preliminary clinical results planned for late 2026</em></li><li style="margin-bottom:6pt; text-align:left;"><em>MGC030 IND application submission cleared ahead of schedule, with first patient expected to be dosed in third quarter</em></li><li style="margin-bottom:6pt; text-align:left;"><em>Pro forma cash, cash equivalents and marketable securities of $327 million; cash runway guidance through 2028</em><br/><br/></li></ul> <p align="left">ROCKVILLE, http://www.streetinsider.com/Globe+Newswire/MacroGenics+Reports+Second+Quarter+2026+Financial+Results%2C+Streamlined+Operating+Model+and+Strengthened+Financial+Position/26920776.html Thu, 13 Aug 2026 16:05:00 -0400 A.06822034 A.50200911 MGNX O.00725647 O.06886563 O.20026344 http://www.streetinsider.com/Globe+Newswire/MacroGenics+Reports+Second+Quarter+2026+Financial+Results%2C+Streamlined+Operating+Model+and+Strengthened+Financial+Position/26920776.html <ul type="disc"><li style="margin-bottom:6pt; text-align:left;"><em>Announced sale of manufacturing operations (July 2026) for $122.5 million and transition to fully outsourced model with leaner, approximately 140-person workforce focused on novel therapeutics pipeline</em></li><li style="margin-bottom:6pt; text-align:left;"><em>Data presentations at ESMO planned for MGC026 (B7-H3 ADC) and lorigerlimab (PD-1 × CTLA-4)</em></li><li style="margin-bottom:6pt; text-align:left;"><em>MGC028 (ADAM9 ADC) dose escalation study ongoing; disclosure of preliminary clinical results planned for late 2026</em></li><li style="margin-bottom:6pt; text-align:left;"><em>MGC030 IND application submission cleared ahead of schedule, with first patient expected to be dosed in third quarter</em></li><li style="margin-bottom:6pt; text-align:left;"><em>Pro forma cash, cash equivalents and marketable securities of $327 million; cash runway guidance through 2028</em><br/><br/></li></ul> <p align="left">ROCKVILLE, http://www.streetinsider.com/Globe+Newswire/MacroGenics+Reports+Second+Quarter+2026+Financial+Results%2C+Streamlined+Operating+Model+and+Strengthened+Financial+Position/26920776.html Thu, 13 Aug 2026 16:05:00 -0400 A.06822034 A.50200911 MGNX O.00725647 O.06886563 O.20026344